Navigation Links
MicroRNA controls expression of oncogenes
Date:6/9/2008

A new study demonstrates that microRNAs can modulate the expression of well known tumor-specific oncogenic translocation proteins and may play a significant role in some human cancers. The research, published by Cell Press in the June issue of the journal Cancer Cell, is likely to lead to new strategies for treating some specific lymphomas and leukemias.

MicroRNAs (miRNAs) are small noncoding pieces of RNA that can modulate the expression of specific target genes. Recent studies have suggested that increases or decreases in miRNA expression may be linked with regulation of oncogenes or tumor suppressors and are therefore likely to play an important role in human cancers.

Dr. Marcos Malumbres from the Spanish National Cancer Research Center (CNIO) in Madrid, Spain and colleagues identified a miRNA-rich chromosomal region in mice that is frequently lost in T cell malignancies. This particular region encodes about 12% of all genomic miRNAs. The researchers used miRNA expression profiling to reveal that one particular miRNA, miR-203, is silenced by both genetic and epigenetic mechanisms in several mouse and human blood cell malignancies, including chronic myelogenous leukemias and some acute lymphoblastic leukemias.

The researchers went on to show that transcriptional silencing of miR-203 lead to upregulation of the oncogene ABL1 and the BCR-ABL1 oncogenic fusion protein in various mouse and human hematopoietic malignancies. Further, restoration of miR-203 resulted in a subsequent reduction of ABL1 and BCR-ABL1 and in decreased proliferation of tumor cells.

"Our results suggest that miR-203 functions as a tumor suppressor and re-expression of this microRNA might have therapeutic benefits in specific hematopoietic malignancies, including some acute or chronic leukemias," concludes Dr. Malumbres. "This may be particularly beneficial for patients who are resistant to small molecule kinase inhibitors like Gleevec as resistant isoforms of ABL and BCR-ABL should contain the target site for miR-203 and are likely to respond to restored miR-203 function."


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. MicroRNAs appear essential for retinal health
2. MicroRNAs, EMT and cancer progression
3. Replacing absent microRNAs could make tumors less invasive, more treatable
4. Single microRNA fine-tunes innate immune response
5. MicroRNAs May Predict Colon Cancer Prognosis
6. 2 microRNAs promote spread of tumor cells
7. Rosetta Genomics Strengthens Senior Management in Preparation for its First Commercial Launch of microRNA-Based Diagnostic Products in 2008
8. Sigma-Aldrich Announces mirPremier(TM) microRNA Isolation Kit for miRNA Purification
9. MicroRNAs may be key to HIVs ability to hide, evade drugs, Jefferson scientists find
10. Monkey Controls Robotic Arm With Brain
11. Stem Cell Marker Controls Pair of Key Cancer Pathways
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... School of Nursing with an in-kind gift of a VeinViewer® Vision vein ... as they learn how to start an IV and draw blood, combining technology ...
(Date:2/13/2016)... Montreal, Canada (PRWEB) , ... February 13, 2016 , ... ... best foot forward. They’ll groom themselves to perfection, go out of their way to ... their date – just take a look at any online dating profile. , ...
(Date:2/12/2016)... ... ... According to an article published February 4th on mySA, robotically ... hernia repairs throughout the United States. Commenting on this article, Beverly Hills hernia repair ... has not only been expected, but it seems to be a natural result of ...
(Date:2/12/2016)... ... ... The law firm of Morrow, Morrow, Ryan & Bassett is offering scholarships to ... to encourage applicants to pursue a degree in their field of study and upon ... “We have available jobs in St. Landry and Evangeline Parishes that can be filled ...
(Date:2/12/2016)... ... 12, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... at its 10th anniversary Fashion Luncheon on Monday, February 8, 2016. The special ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... 12 2016  OMS Supply, a large provider of ... announced today the recent launching of their new company ... of features that enhance the user experience and enable ... --> --> Despite ... company that started in early 2016, they have already ...
(Date:2/12/2016)... Feb. 12, 2016  Apellis Pharmaceuticals, Inc., ... $47.1 million Series D preferred stock financing, ... Hillhouse Capital Group and venBio Global Strategic ... AJU IB Investment, and Epidarex Capital. The proceeds ... further advance clinical trials in the Company,s ...
Breaking Medicine Technology: